next week, page-6

Hi abdm,
I rest from posting on this thread as all what can be said has been said.
People had ample time to read up and research, it is now simply a waiting game.

The fact that it is so silent, in my view, supports the notion that we are nearing something very meaningful, hence the secrecy as updates are not possible briefly before a license deal without revealing the deal itself.
But this is my personal opinion derived from research and anticipation of the conclusion of several testing and evaluation regimes.

Others most likely will disagree, but that is the nature of biotech investing as it greatly depends of speculative combination of sparcely scattered facts.

If one does not appreciate to invest based on such string of information and news one should move onto other sectors as biotech will, in all likelihood, test ones patience.


I certainly agree with your statement that current shareprice does not even remotely incoroparte even ONE single contract in the making.
Market appears to be waiting to read the ann and will rerate on the spot.
So much for the stockmarket being roughly half a year ahead of present events....